WATCH: How Cheech & Chong Turned Their Legacy Into A $100 Million Cannabis Empire https://t.co/n7JN1oE9O4 https://t.co/LIBk9885Zl ...

Industry Overview - The U.S. cannabis industry is experiencing significant growth, with legal sales surpassing $33 billion in 2024 and projected revenues of $50 billion by 2030 [1][3] - Expansion into new adult-use markets and growth in medical programs are creating new opportunities [1][3] - Federal rescheduling and potential banking reforms are increasing optimism in the sector [1][2] Key Companies - Trulieve Cannabis Corp. operates 231 retail dispensaries and has a strong presence in Florida, with a cultivation and processing footprint of over four million square feet [4][7] - Curaleaf Holdings, Inc. operates in 19 states with 154 retail dispensaries and has recently consolidated its international business, enhancing its global position [8][10] - Green Thumb Industries, Inc. operates over 101 retail locations and 20 manufacturing facilities, focusing on both adult-use and medical markets [12][14] Financial Performance - Trulieve reported $302 million in revenue for Q2 2025, with a gross margin of 61% and adjusted EBITDA of $111 million [7][15] - Curaleaf's Q2 2025 net revenue was $314.5 million, an 8% decline from the previous year, with a gross margin of 49% [10][11] - Green Thumb Industries reported Q2 2025 revenue of $293.3 million, a 4.7% increase year-over-year, with a gross margin of 49.9% [14][15] Market Positioning - Trulieve is recognized for its retail penetration and product distribution, supported by a large loyalty program with over 725,000 members [4][7] - Curaleaf's extensive retail and wholesale network positions it well for continued expansion, despite recent revenue challenges [8][11] - Green Thumb's strategy combines brand development with an expanding retail footprint, contributing to steady sales growth [12][14] Investment Considerations - The cannabis sector remains volatile, necessitating careful technical analysis and disciplined risk management for traders [1][2] - Companies with strong fundamentals and expanding footprints are likely to benefit from ongoing industry developments [2][15] - Investors are advised to monitor technical setups while applying risk management strategies to navigate the market effectively [16]

Group 1 - Alan Brochstein is a pioneer in the cannabis investment sector, having focused exclusively on this industry since 2007 [1] - He founded AB Analytical Services to provide independent consulting to registered investment advisors [1] - Brochstein is the managing partner of New Cannabis Ventures, which has been a key provider of financial information in the cannabis industry since 2015 [1] Group 2 - Alan has led the investing group 420 Investor since 2013, which focuses on publicly-traded cannabis stocks [2] - The group covers 20 stocks, providing investment news, earnings report previews, and post-report analyses [2] - Additional features of the group include a model portfolio, 10 weekly videos with chart analysis, 3 weekly summary pieces, a monthly newsletter, and a chat for questions [2]

Group 1 - Xebra Brands Ltd. is an international cannabis company [1] - The company announced a consolidation of its issued and outstanding share capital [1] - The consolidation will be on the basis of one post-consolidation common share for each ten pre-consolidation common shares [1] - The effective date for the consolidation is September 19, 2025 [1]

Core Insights - AYR Wellness Inc. has filed its unaudited interim condensed consolidated financial statements for Q1 2025, ending March 31, 2025 [1] - The financial statements and Management's Discussion and Analysis (MD&A) are available for review on SEDAR+ and the SEC's EDGAR system [2] - Shareholders and interested parties are encouraged to review the filed materials for comprehensive information regarding the Company's operating performance and liquidity position [3] Non-GAAP Measures - The Company reports non-GAAP measures to evaluate business performance and manage capital structure, which may not be comparable to similar measures from other issuers [4] - Non-GAAP measures such as "Adjusted EBITDA" and "Adjusted Gross Profit" are provided to complement GAAP measures and offer further understanding of operational results [5][6] - Adjusted EBITDA is defined as income from continuing operations before interest and taxes, adjusted for non-core costs and non-cash items [7] - Adjusted Gross Profit represents gross profit adjusted for certain costs, including interest and depreciation, with reconciliations provided in the MD&A [8] Company Overview - AYR Wellness is a vertically integrated U.S. multi-state cannabis operator with over 90 licensed dispensaries and a portfolio of cannabis CPG brands [11] - The Company aims to deliver high-quality cannabis products while positively impacting its team members and the communities it serves [11]

Industry Focus Shift - Tilray, once a prominent cannabis company, is now heavily invested in the beer industry [1] Business Strategy - The company's strategic shift involves expanding beyond cannabis into the alcoholic beverage market [1]

WATCH: How Cheech & Chong Turned Their Legacy Into A $100 Million Cannabis Empire https://t.co/l038cafphz https://t.co/QHrusQyAtV ...

carlofranco/iStock via Getty Images Listen here or on the go via Apple Podcasts and Spotify Cannabis has bipartisan support, but is it worthy of your investment? Quant Strategist Emma Johnston covers how quant thinks about sector ETF MSOS (0:25). Buys becoming sells and vice versa (4:55). MSOS risks (8:18). US based cannabis buys (14:40). Is Green Thumb (OTCQX:GTBIF) a buy? (19:45) Transcript Rena Sherbill: Very happy to welcome to Investing Experts, our Quant Strategist, Emma Johnston. Welcome to th ...

Group 1: Industry Overview - The cannabis sector is experiencing a rally due to proposed regulatory changes and potential descheduling of cannabis, which has garnered bipartisan support [4][6][59] - The AdvisorShares Pure US Cannabis ETF (MSOS) is highlighted as a significant investment vehicle with approximately $840 million in assets under management, providing concentrated exposure to the US cannabis market [6][12] - The cannabis industry is characterized by high volatility and regulatory uncertainty, presenting both risks and potential upside for investors [7][10][20] Group 2: ETF Analysis - MSOS has shown excellent momentum and decent liquidity, which has contributed to its recent upgrade from a sell to a buy rating [10][12] - The quant evaluation of ETFs includes metrics such as momentum, expenses, risk, and liquidity, which are crucial for assessing investment opportunities [8][25] - The ETF's structure involves investment swaps to comply with federal regulations, allowing it to gain exposure to US cannabis companies indirectly [21][22] Group 3: Company Insights - Verano Holdings (OTCQX:VRNOF) is identified as a strong buy with a market cap of around $500 million, showing promising growth and profitability metrics despite the overall sector's challenges [27][30] - Vext Science (OTCQX:VEXTF) is another notable company with a market cap of approximately $60 million, demonstrating strong profitability and growth potential [35][36] - Green Thumb (OTCQX:GTBIF) is recognized for its strong balance sheet but faces challenges in growth and earnings revisions, leading to a hold rating [47][50] Group 4: Market Sentiment and Future Outlook - The cannabis sector is viewed as speculative, with investors advised to approach it cautiously, recognizing the potential for both high rewards and significant risks [14][20] - The ongoing political discussions and potential legislative changes are expected to influence market sentiment and investment strategies in the cannabis industry [18][59] - Canadian cannabis companies, such as Tilray (TLRY) and SNDL, are noted for their more mature market presence, offering a different risk profile compared to US-based companies [38][39]

Core Viewpoint - Canopy Growth Corporation has launched a new at-the-market equity program to raise up to $200 million in common shares, aimed at supporting strategic investments and working capital [1][2]. Group 1: Equity Program Details - The new equity program allows for the issuance and sale of up to $200 million in common shares across U.S. and Canadian markets, with Canadian sales capped at $50 million [2]. - The program is governed by an equity distribution agreement dated August 29, 2025, with BMO Nesbitt Burns Inc. and BMO Capital Markets Corp. as agents [3]. - The program will remain active until June 5, 2027, or until the full $200 million is raised, with the Canadian portion ending earlier on July 5, 2026, or upon reaching its $50 million cap [3]. Group 2: Company Overview - Canopy Growth Corporation operates in the cannabis industry, producing and selling cannabis, hemp, and related products across Canada, Germany, and Australia [4]. - The company operates through four segments, including Canada Cannabis and International Markets, offering a variety of products such as dried flower, pre-rolls, edibles, vapes, oils, and concentrates [4]. - Canopy Growth markets its products under multiple brands, including Tweed, 7ACRES, Spectrum Therapeutics, Storz & Bickel, Wana, and DOJA [4].